Press Releases

Extracorporeal CO2 Removal Devices Market is Anticipated to Grow US$ 121.64 Bn By 2030

The Extracorporeal CO2 Removal Devices market is projected to reach US$ 121.64 Bn by 2030. And registering a CAGR of around 7.3% over the forecast period 2021 – 2030.

Download Exclusive Sample of Report@  https://www.visionresearchreports.com/report/sample/38682

Growth Factors

 Technological improvements have changed extracorporeal techniques for CO2 removal in a promising manner to avoid respiratory failure, worsening respiratory acidosis, and to possibly shorten or prevent the duration of invasive mechanical ventilation in patients with exacerbation of asthma and Chronic Obstructive Pulmonary Disease (COPD).

An increasing number of regulatory product approvals for several extracorporeal removal devices during the COVID-19 pandemic helped various market players to increase their product sales. For instance, in April 2020, Alung Technologies received Emergency Use Authorization (EUA) from the U.S. FDA for Hemolung Respiratory Assist System (RAS) for the treatment of COVID-19.

Report Coverage

Report Scope Details
Market Size USD 121.64 million by 2030
Growth Rate CAGR of 7.3% From 2021 to 2030
Base Year 2021
Forecast Period 2021 to 2030
Segments Covered Product, Application, Access, End use
Regional Scope North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Companies Mentioned Medtronic; Getinge AB; Xenios AG; Alung Technologies; ESTOR SpA; Medica SpA; Aferectica Srl

By Product Analysis

The extracorporeal CO2 machines segment accounted for the largest revenue share of 52.3% in 2020. Technical simplification has caused the development and potential applications of extracorporeal CO2 extraction devices to progress rapidly, avoiding nearly some of the initial problems associated with ECMO.

The disposables segment is expected to grow at a significant CAGR of 4.87% over the forecast period. Disposables are used per procedures per patient basis in extracorporeal CO2 removal therapy. High consumption and demand for consumables in such procedures are predicted to augment the segment growth.

By Access Analysis

The venovenous segment accounted for the highest revenue share of 65.30% in 2020. In venovenous access, the blood is drawn from the central vein through a drainage cannula using a roller or centrifugal pump to produce flow across the gas exchange membrane. In recent years, a new generation of extracorporeal CO2 removal devices has been developed.

The arteriovenous segment is estimated to register the fastest CAGR over the forecast years. With arteriovenous extracorporeal CO2 removal devices, the blood flows from the femoral artery with the help of a gas exchanger and returns into the contralateral femoral vein.

By End-use Analysis

The hospitals segment captured the largest revenue share of over 47.36% in 2020. An increasing number of hospital admissions, especially the patients suffering from ARDS due to the recent outbreak of COVID-19, is predicted to boost the segment growth.Rising cases of COPD and ARDS are also anticipated to fuel the product demand in hospitals.

The Ambulatory Surgical Centers (ASCs) segment is projected to register significant CAGR from 2021 to 2030. This growth can be accredited to the rising cases of acute respiratory failure, especially in rural areas that have limited access to healthcare services.

By Application Analysis

 The bridge to lung transplant segment accounted for the largest revenue share of more than 40% in 2020. Patients waiting for lung transplantation that develop life-threatening hypercarbia may benefit from extracorporeal CO2 removal devices by using them as a bridge to transplantation.

The rising focus of manufacturers, such as Alung Technologies and Xenios AG, on developing extracorporeal CO2 removal devices for bridge to lung transplantation is anticipated to spur the market growth during the forecast period.

By Regional Analysis

Asia Pacific is anticipated to register the largest CAGR of 8.24% during the forecast period. The presence of a large patient pool, rising awareness regarding acute respiratory failure, increasing government healthcare expenditure in developing countries, such as India and Japan, are predicted to accelerate the regional market growth.

A huge population base with low per capita income in the region leads to high demand for affordable treatment options. Thus, multinational companies are looking forward to investing in developing countries, such as China, anticipating regional market growth.

Early adoption of novel technologies and a large patient pool of ARDS and COPD are also anticipated to accelerate the regional market growth. In addition, increasing cases of chronic respiratory diseases are anticipated to create demand for extracorporeal CO2 removal devices.

The market in Europe is expected to expand at the second-fastest CAGR of over 7% during the forecast period. Increasing demand for healthcare devices coupled with the rising prevalence of chronic diseases, such as respiratory failure, is expected to drive the regional market.

Key Players

  • Medtronic
  • Getinge AB
  • Xenios AG
  • Alung Technologies
  • ESTOR SpA
  • Medica SpA
  • Aferectica Srl

Market Segmentation

  • Product
    • Extracorporeal CO2 Machines
    • Disposables
    • Others
  • Application
    • Acute Respiratory Distress Syndrome (ARDS)
    • Chronic Obstructive Pulmonary Disease (COPD)
    • Bridge to Lung Transplant
    • Others
  • Access
    • Venovenous
    • Arteriovenous
  • End-use
    • Hospitals
    • Ambulatory Surgical Centers
    • Clinics
    • Others
  • Regional
    • North America
      • U.S.
      • Canada
    • Europe
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
    • Asia Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
    • Latin America
      • Brazil
      • Mexico
      • Argentina
      • Colombia
    • Middle East & Africa
      • South Africa
      • Saudi Arabia
      • UAE

Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/38682

Reasons to Purchase this Report:

– Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
– Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
– Market value USD Million and volume Units Million data for each segment and sub-segment
– Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
– Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players

Table of Contents

Chapter 1.  Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Market Snapshot

Chapter 4.  Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Material Procurement Analysis

4.3.2.    Sales and Distribution Channel Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.  Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.    Market Drivers

5.1.2.    Market Restraints

5.1.3.    Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.    Bargaining power of suppliers

5.2.2.    Bargaining power of buyers

5.2.3.    Threat of substitute

5.2.4.    Threat of new entrants

5.2.5.    Degree of competition

Chapter 6.  Competitive Landscape

6.1.1.    Company Market Share/Positioning Analysis

6.1.2.    Key Strategies Adopted by Players

6.1.3.    Vendor Landscape

6.1.3.1.        List of Suppliers

6.1.3.2.        List of Buyers

Chapter 7.  Global Extracorporeal CO2 Removal Devices Market, By Product

7.1.  Extracorporeal CO2 Removal Devices Market, by Product, 2021-2030

7.1.1.    Extracorporeal CO2 Machines

7.1.1.1.        Market Revenue and Forecast (2017-2030)

7.1.2.    Disposables

7.1.2.1.        Market Revenue and Forecast (2017-2030)

7.1.3.    Others

7.1.3.1.        Market Revenue and Forecast (2017-2030)

Chapter 8.  Global Extracorporeal CO2 Removal Devices Market, By Application

8.1.  Extracorporeal CO2 Removal Devices Market, by Application, 2021-2030

8.1.1.    Acute Respiratory Distress Syndrome (ARDS)

8.1.1.1.        Market Revenue and Forecast (2017-2030)

8.1.2.    Chronic Obstructive Pulmonary Disease (COPD)

8.1.2.1.        Market Revenue and Forecast (2017-2030)

8.1.3.    Bridge to Lung Transplant

8.1.3.1.        Market Revenue and Forecast (2017-2030)

8.1.4.    Others

8.1.4.1.        Market Revenue and Forecast (2017-2030)

Chapter 9.  Global Extracorporeal CO2 Removal Devices Market, By End User

9.1.  Extracorporeal CO2 Removal Devices Market, by End User, 2021-2030

9.1.1.    Hospitals

9.1.1.1.        Market Revenue and Forecast (2017-2030)

9.1.2.    Ambulatory Surgical Centers

9.1.2.1.        Market Revenue and Forecast (2017-2030)

9.1.3.    Clinics

9.1.3.1.        Market Revenue and Forecast (2017-2030)

9.1.4.    Others

9.1.4.1.        Market Revenue and Forecast (2017-2030)

Chapter 10.      Global Extracorporeal CO2 Removal Devices Market, By Access

10.1.        Extracorporeal CO2 Removal Devices Market, by Access, 2021-2030

10.1.1.  Venovenous

10.1.1.1.      Market Revenue and Forecast (2017-2030)

10.1.2.  Arteriovenous

10.1.2.1.      Market Revenue and Forecast (2017-2030)

Chapter 11.      Global Extracorporeal CO2 Removal Devices Market, Regional Estimates and Trend Forecast

11.1.        North America

11.1.1.  Market Revenue and Forecast, by Product (2017-2030)

11.1.2.  Market Revenue and Forecast, by Application (2017-2030)

11.1.3.  Market Revenue and Forecast, by End User (2017-2030)

11.1.4.  Market Revenue and Forecast, by Access (2017-2030)

11.1.5.  U.S.

11.1.5.1.      Market Revenue and Forecast, by Product (2017-2030)

11.1.5.2.      Market Revenue and Forecast, by Application (2017-2030)

11.1.5.3.      Market Revenue and Forecast, by End User (2017-2030)

11.1.5.4.      Market Revenue and Forecast, by Access (2017-2030)

11.1.6.  Rest of North America

11.1.6.1.      Market Revenue and Forecast, by Product (2017-2030)

11.1.6.2.      Market Revenue and Forecast, by Application (2017-2030)

11.1.6.3.      Market Revenue and Forecast, by End User (2017-2030)

11.1.6.4.      Market Revenue and Forecast, by Access (2017-2030)

11.2.        Europe

11.2.1.  Market Revenue and Forecast, by Product (2017-2030)

11.2.2.  Market Revenue and Forecast, by Application (2017-2030)

11.2.3.  Market Revenue and Forecast, by End User (2017-2030)

11.2.4.  Market Revenue and Forecast, by Access (2017-2030)

11.2.5.  UK

11.2.5.1.      Market Revenue and Forecast, by Product (2017-2030)

11.2.5.2.      Market Revenue and Forecast, by Application (2017-2030)

11.2.5.3.      Market Revenue and Forecast, by End User (2017-2030)

11.2.5.4.      Market Revenue and Forecast, by Access (2017-2030)

11.2.6.  Germany

11.2.6.1.      Market Revenue and Forecast, by Product (2017-2030)

11.2.6.2.      Market Revenue and Forecast, by Application (2017-2030)

11.2.6.3.      Market Revenue and Forecast, by End User (2017-2030)

11.2.6.4.      Market Revenue and Forecast, by Access (2017-2030)

11.2.7.  France

11.2.7.1.      Market Revenue and Forecast, by Product (2017-2030)

11.2.7.2.      Market Revenue and Forecast, by Application (2017-2030)

11.2.7.3.      Market Revenue and Forecast, by End User (2017-2030)

11.2.7.4.      Market Revenue and Forecast, by Access (2017-2030)

11.2.8.  Rest of Europe

11.2.8.1.      Market Revenue and Forecast, by Product (2017-2030)

11.2.8.2.      Market Revenue and Forecast, by Application (2017-2030)

11.2.8.3.      Market Revenue and Forecast, by End User (2017-2030)

11.2.8.4.      Market Revenue and Forecast, by Access (2017-2030)

11.3.        APAC

11.3.1.  Market Revenue and Forecast, by Product (2017-2030)

11.3.2.  Market Revenue and Forecast, by Application (2017-2030)

11.3.3.  Market Revenue and Forecast, by End User (2017-2030)

11.3.4.  Market Revenue and Forecast, by Access (2017-2030)

11.3.5.  India

11.3.5.1.      Market Revenue and Forecast, by Product (2017-2030)

11.3.5.2.      Market Revenue and Forecast, by Application (2017-2030)

11.3.5.3.      Market Revenue and Forecast, by End User (2017-2030)

11.3.5.4.      Market Revenue and Forecast, by Access (2017-2030)

11.3.6.  China

11.3.6.1.      Market Revenue and Forecast, by Product (2017-2030)

11.3.6.2.      Market Revenue and Forecast, by Application (2017-2030)

11.3.6.3.      Market Revenue and Forecast, by End User (2017-2030)

11.3.6.4.      Market Revenue and Forecast, by Access (2017-2030)

11.3.7.  Japan

11.3.7.1.      Market Revenue and Forecast, by Product (2017-2030)

11.3.7.2.      Market Revenue and Forecast, by Application (2017-2030)

11.3.7.3.      Market Revenue and Forecast, by End User (2017-2030)

11.3.7.4.      Market Revenue and Forecast, by Access (2017-2030)

11.3.8.  Rest of APAC

11.3.8.1.      Market Revenue and Forecast, by Product (2017-2030)

11.3.8.2.      Market Revenue and Forecast, by Application (2017-2030)

11.3.8.3.      Market Revenue and Forecast, by End User (2017-2030)

11.3.8.4.      Market Revenue and Forecast, by Access (2017-2030)

11.4.        MEA

11.4.1.  Market Revenue and Forecast, by Product (2017-2030)

11.4.2.  Market Revenue and Forecast, by Application (2017-2030)

11.4.3.  Market Revenue and Forecast, by End User (2017-2030)

11.4.4.  Market Revenue and Forecast, by Access (2017-2030)

11.4.5.  GCC

11.4.5.1.      Market Revenue and Forecast, by Product (2017-2030)

11.4.5.2.      Market Revenue and Forecast, by Application (2017-2030)

11.4.5.3.      Market Revenue and Forecast, by End User (2017-2030)

11.4.5.4.      Market Revenue and Forecast, by Access (2017-2030)

11.4.6.  North Africa

11.4.6.1.      Market Revenue and Forecast, by Product (2017-2030)

11.4.6.2.      Market Revenue and Forecast, by Application (2017-2030)

11.4.6.3.      Market Revenue and Forecast, by End User (2017-2030)

11.4.6.4.      Market Revenue and Forecast, by Access (2017-2030)

11.4.7.  South Africa

11.4.7.1.      Market Revenue and Forecast, by Product (2017-2030)

11.4.7.2.      Market Revenue and Forecast, by Application (2017-2030)

11.4.7.3.      Market Revenue and Forecast, by End User (2017-2030)

11.4.7.4.      Market Revenue and Forecast, by Access (2017-2030)

11.4.8.  Rest of MEA

11.4.8.1.      Market Revenue and Forecast, by Product (2017-2030)

11.4.8.2.      Market Revenue and Forecast, by Application (2017-2030)

11.4.8.3.      Market Revenue and Forecast, by End User (2017-2030)

11.4.8.4.      Market Revenue and Forecast, by Access (2017-2030)

11.5.        Latin America

11.5.1.  Market Revenue and Forecast, by Product (2017-2030)

11.5.2.  Market Revenue and Forecast, by Application (2017-2030)

11.5.3.  Market Revenue and Forecast, by End User (2017-2030)

11.5.4.  Market Revenue and Forecast, by Access (2017-2030)

11.5.5.  Brazil

11.5.5.1.      Market Revenue and Forecast, by Product (2017-2030)

11.5.5.2.      Market Revenue and Forecast, by Application (2017-2030)

11.5.5.3.      Market Revenue and Forecast, by End User (2017-2030)

11.5.5.4.      Market Revenue and Forecast, by Access (2017-2030)

11.5.6.  Rest of LATAM

11.5.6.1.      Market Revenue and Forecast, by Product (2017-2030)

11.5.6.2.      Market Revenue and Forecast, by Application (2017-2030)

11.5.6.3.      Market Revenue and Forecast, by End User (2017-2030)

11.5.6.4.      Market Revenue and Forecast, by Access (2017-2030)

Chapter 12.  Company Profiles

12.1.              Medtronic

12.1.1.  Company Overview

12.1.2.  Product Offerings

12.1.3.  Financial Performance

12.1.4.  Recent Initiatives

12.2.              Getinge AB

12.2.1.  Company Overview

12.2.2.  Product Offerings

12.2.3.  Financial Performance

12.2.4.  Recent Initiatives

12.3.              Xenios AG

12.3.1.  Company Overview

12.3.2.  Product Offerings

12.3.3.  Financial Performance

12.3.4.  Recent Initiatives

12.4.              Alung Technologies

12.4.1.  Company Overview

12.4.2.  Product Offerings

12.4.3.  Financial Performance

12.4.4.  Recent Initiatives

12.5.              ESTOR SpA

12.5.1.  Company Overview

12.5.2.  Product Offerings

12.5.3.  Financial Performance

12.5.4.  Recent Initiatives

12.6.              Medica SpA

12.6.1.  Company Overview

12.6.2.  Product Offerings

12.6.3.  Financial Performance

12.6.4.  Recent Initiatives

12.7.              Aferectica Srl

12.7.1.  Company Overview

12.7.2.  Product Offerings

12.7.3.  Financial Performance

12.7.4.  Recent Initiatives

Chapter 13.  Research Methodology

13.1.              Primary Research

13.2.              Secondary Research

13.3.              Assumptions

Chapter 14.  Appendix

14.1.              About Us

14.2.              Glossary of Terms

Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/38682

Contact Us:

Vision Research Reports

Call: +1 9197 992 333

Email: sales@visionresearchreports.com

Show More

Related Articles

Back to top button